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Purpose: The objective of this report was to
determine the pharmacokinetic properties, safety,
and tolerability of single and multiple doses of intra-
venous delaﬂoxacin. In addition, the absolute bioa-
vailability (BA) of the 450-mg tablet formulation of
delaﬂoxacin was determined.
Methods: Three clinical trials are summarized. The
ﬁrst study was a randomized, double-blind, placebo-
controlled, single- (300, 450, 600, 750, 900, and
1200 mg) ascending-dose study of IV delaﬂoxacin in
62 (52 active, 10 placebo) healthy volunteers. The
second study was a randomized, double-blind,
placebo-controlled study of IV delaﬂoxacin (300 mg)
given as a single dose on day 1, followed by twice-
daily dosing on days 2 through 14; 12 (8 active, 4
placebo) healthy volunteers were enrolled. The third
study was an open-label, randomized, 2-period,
2-sequence crossover study in which 56 healthy
volunteers were randomly assigned to 1 of 2 sequences
of a single oral dose of delaﬂoxacin (450-mg tablet) or
IV delaﬂoxacin (300 mg). Serial blood samples were
collected, and plasma pharmacokinetic parameters of
delaﬂoxacin were calculated.
Findings: Delaﬂoxacin Cmax values increased pro-
portionally with increasing single IV dose for the dose
range of 300 to 1200 mg, whereas the AUC values
increased more than proportionally to dose for the same
dose range. The mean terminal half-life of delaﬂoxacin
was approximately 12 hours (ranging from 8 to 17
hours). The volume of distribution (Vd) at steady state
was approximately 35 L, which is similar to the volume
of total body water. There was minimal accumulation
of delaﬂoxacin after twice-daily IV administration of
300 mg with an accumulation ratio of 1.09. The
delaﬂoxacin total exposure after a single 1-hour IV
infusion of 300 mg and a single oral dose of a 450-mgJanuary 2016tablet were equivalent with geometric least square
mean ratio (90% CI) of 0.8768 (0.8356–0.9200) for
AUC0–1 and 0.8445 (0.8090–0.8815) for AUC0–t,
respectively. The Cmax values of delaﬂoxacin were not
equivalent for the 2 formulations with a ratio (90% CI)
of 0.5516 (0.5150–0.5908), respectively. The mean
absolute bioavailability of delaﬂoxacin was 58.8%.
Implications: Delaﬂoxacin was well tolerated in
healthy volunteers after single and multiple IV doses.
The total systemic exposure to IV (300 mg) and oral
(450 mg) delaﬂoxacin is comparable, supporting that
a switch between the 2 formulations is appropriate.
(Clin Ther. 2016;38:53–65) & 2016 The Authors.
Published by Elsevier HS Journals, Inc.
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Delaﬂoxacin (RX-3341, ABT-492, WQ-3034) is an
investigational anionic ﬂuoroquinolone antibiotic that
is currently in Phase III development for the treatment
of acute bacterial skin and skin structure infect-
ions (ABSSSIs). Delaﬂoxacin has a broad spectrum
of activity against gram-positive pathogens, inclu-
ding methicillin-susceptible Staphylococcus aureus,
methicillin-resistant strains of S aureus (MRSA),
Streptococcus pyogenes, and enterococci, while main-
taining activity against gram-negative pathogens and53
Clinical Therapeuticsanaerobes.1–3 Delaﬂoxacin is unique in that its anti-
bacterial potency increases as the pH of the local
environment becomes more acidic, a characteristic of
infection settings.4
Delaﬂoxacin has excellent in vitro activity against
MRSA, with an MIC90 ranging from 0.12 to 0.5 mg/mL.
5
In a Phase II study of ABSSSIs, intravenous delaﬂoxacin
had comparable cure rates with linezolid but statistically
greater cure rates when compared with vancomycin.6
In a second Phase II study of complicated skin and skin-
structure infections, delaﬂoxacin had comparable cure
rates with tigecycline.7 Delaﬂoxacin has been generally
well tolerated, with mild to moderate gastrointestinal
adverse events (AEs) being most common.6,7 Delaﬂoxacin
has a very low potential for phototoxicity and has no
effect on the QT interval.8,9 Both intravenous and oral
formulations of delaﬂoxacin are being developed, which
would enable the possibility of patients to switch from
intravenous to oral therapy. The doses of delaﬂoxacin
being evaluated in Phase III for treatment of ABSSSIs are
300 mg and 450 mg for IV and oral administration,
respectively.
The disposition of delaﬂoxacin after a single 300-mg
IV dose has been studied in a mass-balance study using
radiolabeled delaﬂoxacin in healthy male volunteers.10
Delaﬂoxacin was predominantly excreted by the
kidney, with 66% of a single intravenous dose
recovered in the urine, most of which was unchanged
delaﬂoxacin. Approximately 29% of the radioactivity
was recovered in the feces, which was likely due to
biliary excretion and/or transintestinal elimination.
Delaﬂoxacin undergoes minimal oxidative metabolism,
and excretion of acyl glucuronides in urine represented
r20% of the administered intravenous dose.
The present report describes the results of 3 studies
conducted to determine the safety, tolerability, and
pharmacokinetic properties of intravenous delaﬂoxacin
after single and multiple doses in healthy volunteers. In
addition, a comparative bioavailability study was con-
ducted to determine whether systemic exposure to
delaﬂoxacin is equivalent for the IV 300-mg and oral
450-mg doses, which would support the appropriate-
ness of a switch between the 2 formulations.PATIENTS AND METHODS
The 3 studies reported here were conducted according
to good clinical practice and all applicable guidelines
following the ethical principles of the Declaration of54Helsinki. An independent ethics committee reviewed
and approved the protocol and written informed
consent for each of the 3 studies. The volunteers
signed written informed consent forms.
Study Population
Study participants were healthy male and female
adults (18 to 64 years old) with a body mass index
between 19 and 32 kg/m2. Participants were enrolled
based on review of medical history, physical exami-
nation, vital signs, clinical laboratory tests, and ECG.
Participants were nonsmokers and did not have a
history of drug or alcohol abuse. Female participants
were not pregnant or breastfeeding. Concomitant
medications were not allowed 14 days (or 7 days for
over-the-counter medications) before study start and
through completion of exit procedures. The use of
intravenous or oral antibiotics within 4 weeks of ﬁrst
dose of study drug was prohibited.
Study Designs
The ﬁrst study was a double-blind, randomized,
single-ascending-dose study conducted in 62 healthy
male and female volunteers. Twelve volunteers received
a single IV 1-hour infusion of 300 mg of delaﬂoxa-
cin. The remaining 50 volunteers received a single IV
1-hour infusion of 450, 600, 750, 900, or 1200 mg
delaﬂoxacin (8 per dose group) or placebo (2 per dose
group). Blood samples were collected before dosing and
at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 20, 24,
36, and 48 hours after dosing. Urine samples for
measurement of delaﬂoxacin concentrations were col-
lected before dosing and at 0 to 4, 4 to 8, 8 to 12, 12 to
24, 24 to 36, and 36 to 48 hours after dosing. The
safety proﬁle and tolerability of the preceding dose was
conﬁrmed before escalation to the next dose level.
The second study was a randomized, double-blind,
placebo-controlled study to evaluate the pharmacoki-
netic properties, safety proﬁle, and tolerability of multi-
ple IV doses (300 mg infused for 1 hour) of delaﬂoxacin
in 12 healthy male and female volunteers. The volun-
teers received a single 300-mg IV infusion of delaﬂox-
acin (n ¼ 8) or placebo (n ¼ 4) on day 1. On days 2
through 14, delaﬂoxacin (300 mg) was administered
twice daily as two 1-hour infusions given 12 hours
apart. Blood samples were collected on day 1 and day
14 before dosing, at 0.5 hours during the infusion, and
at 1, 1.083, 1.167, 1.33, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 (day
1 only), and 24 (day 1 only) hours after dosing. On daysVolume 38 Number 1
R. Hoover et al.3, 7, and 10, blood samples were collected just before
the morning and evening doses. Urine samples were
collected on day 1 (before dosing, at 0-12 hours after
dosing, and at 12-24 hours after dosing) and on day 14
(before dosing, at 0-12 hours after dosing).
In the third study, the safety proﬁle and tolerability of
intravenous and oral delaﬂoxacin were evaluated in an
open-label, randomized, 2-period, 2-sequence crossover
study. A total of 56 healthy male and female volunteers
were randomly assigned in a 1:1 ratio to a single dose of
oral delaﬂoxacin (450-mg tablet) and IV delaﬂoxacin
(300 mg infused for 1 hour). Volunteers fasted at least 8
hours before delaﬂoxacin administration and continued
to fast until 4 hours after study drug administration.
Blood samples were collected to determine delaﬂoxacin
plasma concentrations before dosing and at 0.25, 0.5,
0.75, 1 (end of infusion for intravenous, 1 hour after
dosing for oral), 1.25, 1.5, 2, 3, 4, 6, 8, 12, 16, 20, 24,
30, 36, 48, and 72 hours after dosing in each period.
The safety proﬁle was monitored throughout the
studies by physical examinations, vital signs, ECGs,
laboratory evaluations, and the assessment of AEs. A
sulfobutyl-ether-β-cyclodextrin (SBEβCD)*-containing
formulation of intravenous delaﬂoxacin was used in
all 3 studies.
Bioanalytical Methods
Plasma and urine samples were extracted with
hexane:ethyl acetate, analyzed using validated liquid
chromatography–tandem mass spectrometry methods
(assay ranges of 5.00 to 5000 ng/mL and 50.0 to
10000 ng/mL, respectively), and subjected to isocratic
reverse-phase HPLC. Quantitation was accomplished
by triple-quadrupole mass spectrometry, monitoring
the precursor-to-product ion reaction channels: m/z
441-379 for delaﬂoxacin, m/z 407-345 for an
analog internal standard, or 446-381 for the deuter-
ated delaﬂoxacin internal standard. The mean accuracy
was within 85% to 115% of theoretical, and the
precision of the assay did not exceed a %CV of 15%.
Pharmacokinetic Analysis
Pharmacokinetic parameters were calculated by
noncompartmental methods using SAS software, ver-
sion 9.1 or higher (SAS Institute, Cary, North Caro-
lina). The Tmax and Cmax were the observed values.*Trademark: Captisols (Ligand Technology, La Jolla,
California).
January 2016The terminal elimination rate (λZ) was determined
from the slope of a least-squared linear regression of
the log of the plasma concentrations from the terminal
log-linear phase. The AUC0–t, AUC0–12, or AUC0–24
was calculated by the linear trapezoidal method. The
AUC was extrapolated to inﬁnite time (AUCext) by
dividing the last measurable plasma concentration by
λZ. The AUC0–1 was calculated as AUC0–1 ¼ AUC0–t
þ AUCext. The clearance (CL) was calculated by
dividing the administered dose by the AUC0–1 (single
dose) or AUC0–12 (after 14 days of dosing). The
volume of distribution (Vd) in the terminal phase was
CL/λZ. The Vd at steady state was mean residence time
divided by CL. The accumulation ratio (Rac) was the
ratio of the day 14 AUC0–12 to the day 1 AUC0–12.
The percentage of dose recovered as unchanged
delaﬂoxacin in urine was calculated as the total
amount of delaﬂoxacin recovered in urine (Au) for
the 24-hour or 48-hour interval after the single dose
on day 1 or the 12-hour interval after the ﬁrst dose on
day 14 divided by the total administered dose and
multiplied by 100. Renal clearance (CLr) was Au
divided by AUC0–24 or AUC0–48 after the single dose
on day 1 or Au/AUC0–12 after the ﬁrst dose on day 14.
Statistical Analysis
Statistical analysis was conducted using SAS soft-
ware, version 9.1 or higher (SAS Institute). A dose
proportionality assessment was performed on Cmax,
AUC0–t, and AUC0–1 using a power model. Dose
proportionality was considered to be ruled out if 1
was not included in the 90% CI of the slope of a linear
regression of the ln-transformed parameters. To com-
pare the relative exposures of oral delaﬂoxacin
(450 mg) to IV delaﬂoxacin (300 mg), a linear
mixed-effect model was performed on the ln-
transformed values of Cmax, AUC0–t, and AUC0–1
with sequence, treatment, and period as ﬁxed effects
and subject nested within sequence as a random effect.
The geometric least squares mean ratio of the 2
treatments for the pharmacokinetic parameters was
calculated by an antilog of the least squares mean
difference of the log-transformed values. A 90% CI
for the ratio was constructed as the antilog of the
conﬁdence limits of the least squares mean difference.
No adjustment was made for multiplicity. Equivalence
in total exposure was concluded if the 90% CI of the
ratios of geometric means were entirely contained
with 80% to 125% for AUC0–t and AUC0–1.55
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Clinical TherapeuticsSafety Analysis
Safety parameters were monitored throughout all 3
studies by physical examinations, vital signs, ECGs,
laboratory evaluations, and the assessment of AEs.T
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Study Population
A summary of the demographic characteristics of the
study participants for the 3 studies is presented in
Table I. A total of 94 healthy men and women were
enrolled across the 3 studies. Their demographic
characteristics were generally consistent across
studies. One volunteer in the multiple-dose study
discontinued participation early because of an AE of
nausea and vomiting. Two volunteers in the relative
bioavailability study discontinued participation early
because they tested positive for ethanol.
Pharmacokinetic Properties of Delafloxacin after
Single Ascending Doses
The mean plasma concentration-time proﬁles after
single-ascending doses (300–1200 mg) of delaﬂoxacin
are shown in Figure 1. The mean (SD) pharmaco-
kinetic parameters for the single-ascending-dose study
(300–1200 mg) are listed in Table II. The Tmax of
delaﬂoxacin was at the end of infusion for all dose
levels. The plasma concentration proﬁles decreased
biexponentially with a mean terminal half-life of ap-
proximately 12 hours for most doses (450 mg, 600 mg,
900 mg, and 1200 mg) but ranged from 8.21 (300 mg)
to 17.74 (750 mg) hours. The terminal half-life could
not be determined in several participants because of the
limits of the sampling schedule, the limit of quantitation,
and long terminal half-life. The terminal half-life gen-
erally accounted for only a small portion of the AUC.
The Vd at steady state ranged from 30.21 to 38.46 L
and was dose independent. Clearance ranged 7.59 to
12.53 L/h and tended to decrease with increasing dose.
Statistical analysis of dose proportionality revealed that
Cmax increased proportionally in the 300- to 1200-mg
dose range, whereas AUC0–t and AUC0–1 increased
more than proportionally in this dose range (Table III).
Applying the method of Smith et al11 to establish dose
proportionality, the criterion 90% CI for the slope of the
parameters for the range of evaluated doses is 0.96 to
1.14. The estimated slopes for the AUC values were
completely outside the criterion 90% CI, whereas the
slope for Cmax was completely within the interval. When56 Volume 38 Number 1
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Figure 1. Mean (SD) plasma concentration-time
curves of delafloxacin after single IV
1-hour infusions of 300 to 1200 mg.
Top, linear plot; bottom, semilog plot.
R. Hoover et al.doses increased in ratios of 1.5 (450 mg/300 mg),
2 (600 mg/300 mg), 2.5 (750 mg/300 mg), 3 (900
mg/300 mg), and 4 (1200 mg/300 mg), the corres-
ponding means ratios for AUC0–1 were approximately
1.7, 2.4, 3.0, 4.0, and 6.4, respectively. The corres-
ponding Cmax ratios were 1.5, 2.2, 2.5, 2.8, and 4.7,
respectively. The percentage of delaﬂoxacin recovered in
the urine ranged from 30% to 40%. The CLr decreased
slightly with increasing dose at 4.98 L/h for 300 mg to
2.64 L/h for 1200 mg, respectively.Pharmacokinetic Properties of Delafloxacin After
Multiple Doses
The mean (SD) pharmacokinetic parameters after
multiple 300-mg IV infusion doses of delaﬂoxacin are
listed in Table II. The pharmacokinetic parameters of
delaﬂoxacin did not change as a result of repeatedJanuary 2016dosing. The Cmax values for delaﬂoxacin on days 1
and 14 were 8.94 and 9.29 mg/mL, respectively. The
AUC0–12 values for delaﬂoxacin on days 1 and 14
were 21.8 h  mg/mL and 23.4 h  mg/mL, respectively.
There was no appreciable accumulation of delaﬂo-
xacin after 14 days of twice-daily dosing as indicated
by a mean Rac of 1.09. Mean delaﬂoxacin CL was
similar on day 1 (14.1 L/h) and day 14 (13.8 L/h). The
CLr of delaﬂoxacin was also comparable on day 1
(5.89 L/h) and day 14 (6.69 L/h).
Absolute Bioavailability
The mean plasma concentration-time proﬁles of
delaﬂoxacin after single IV (300 mg) and oral
(450 mg) doses are shown in Figure 2, and the
pharmacokinetic parameters of delaﬂoxacin are
given in Table IV. A summary of the statistical
analysis of bioequivalence of the 2 formulations is
given in Table V. Equivalence in delaﬂoxacin total
exposure (AUC0–t and AUC0–1) after intravenous
(reference) and oral (test) delaﬂoxacin was found
because the 90% CI of the ratios of geometric
means was contained within the 80% to 125%
interval. There was no statistically signiﬁcant
sequence or period effect. Cmax was not equivalent
for the intravenous and oral doses because the test-to-
reference ratios were outside the 80% to 125%
interval. The mean absolute bioavailability of dela-
ﬂoxacin was 58.8%.
Safety Profile and Tolerability
Delaﬂoxacin was well tolerated in all 3 studies
(Table VI). There were no clinically signiﬁcant
ﬁndings resulting from clinical laboratory assess-
ments, vital signs, ECG results, or physical examin-
ations in the 3 studies. In the single-ascending-dose
study, a total of 16 participants (32%) reported a
treatment-emergent AE, most of which were classiﬁed
as gastrointestinal disorders (primarily nausea, vomit-
ing, and diarrhea) and nervous system disorders. Most
AEs were classiﬁed as mild and considered possibly
related to delaﬂoxacin. The AEs of nausea and
vomiting were dose related, with few events reported
at the 300-mg dose level. The 1200-mg treatment
groups reported the largest number of AEs, which
were primarily gastrointestinal events, with most of
moderate severity and probably related to delaﬂox-
acin. In the multiple-dose study, 75% of participants
in the placebo and delaﬂoxacin groups reported a57
Table II. Mean (SD) pharmacokinetic parameters of delafloxacin after a single or multiple IV 1-hour infusion to healthy volunteers.
Pharmacokinetic
Parameter
Delafloxacin Single IV Infusion (SBEβCD Lyophilized)
Delafloxacin Multiple IV
Infusion (Cyclodextrin
Solution), 300 mg BID*
300 mg
(n ¼ 12)
450 mg
(n ¼ 8)
600 mg
(n ¼ 8)
750 mg
(n ¼ 8)
900 mg
(n ¼ 8)
1200 mg
(n ¼ 8)
Day 1
(n ¼ 8)
Day 14
(n ¼ 7)
Cmax, mg/mL 10.4 (1.95) 16.1 (2.01) 23.0 (4.82) 26.2 (3.94) 29.7 (4.67) 49.1 (12.38) 8.94 (4.54) 9.29 (1.83)
Tmax, h
† 1.00 (0.97–1.08) 1.00 (1.00–1.00) 1.02 (1.00–1.03) 1.00 (1.00–1.15) 1.00 (1.00–1.03) 1.02 (0.80–1.05)
AUC0–t, mg  h/mL 24.7 (4.89) 42.6 (7.26) 61.5 (15.0) 74.0 (20.1) 98.1 (28.3) 156 (27.8)
AUC0–1, mg  h/mL 24.8 (4.87)‡ 42.9 (7.24) 59.0 (13.7)‡ 74.4 (3.49)‡ 99.3 (26.0)‡ 160 (18.5)‡ 22.1 (4.45)§ ND
AUC12 (mg  h/mL)§ 21.8 (4.54) 23.4 (6.90)
t½, h 8.21 (2.72)
‡ 12.5 (5.46) 11.9 (5.32)‡ 17.7 (2.40)‡ 11.6 (7.79)‡ 11.7 (4.00)‡
CL, L/h 12.53 (2.64)‡ 10.8 (1.91) 10.6 (2.36)‡ 10.1 (0.48)‡ 9.65 (2.80)‡ 7.59 (0.96)‡ 14.1 (2.81)§ ND
Vss, L 34.2 (6.73)
‡ 36.6 (9.57) 38.5 (12.6)‡ 32.9 (4.15)‡ 36.4 (6.71)‡ 30.2 (4.29)‡
VZ, L 146.1 (50.3)
‡ 198 (110) 194 (128)‡ 257 (23.5)‡ 148 (75.5)‡ 131 (58.1)‡
Ae0–48, mg 117 (26.8) 165 (34.4) 226 (29.0) 235 (65.5) 304 (68.1) 410 (100)
Fe%00–48, % 38.9 (8.92) 36.7 (7.65) 37.7 (4.83) 31.4 (8.73) 33.8 (7.57) 34.1 (8.36)
Rac ND 1.09 (0.123)
CLr, L/h 4.98 (1.66) 4.04 (1.39) 3.95 (1.36) 3.24 (0.80) 3.47 (1.76) 2.64 (0.50) 5.89 (1.55) 6.69 (2.19)
ND ¼ not determined; SBEβCD ¼ sulfobutyl-ether-β-cyclodextrin.
*On day 1, a single IV dose of 300 mg of delaﬂoxacin (1-hour infusion) was given at 0 hour. On days 2 through 14, a 300-mg dose of delaﬂoxacin (IV 1-hour infusion)
was administered BID at 0 and 12 hours.
†Median (range).
‡n ¼ 9 for the 300-mg group, n ¼ 7 for the 600-mg group, n ¼ 3 for the 750-mg group, and n ¼ 6 for the 900-mg and 1200-mg groups.
§n ¼ 7.
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Table III. Statistical analysis of dose proportionality.*
Parameter
Estimated Slope (90% CI) for Ln (Dose) for the Delafloxacin
300- to 1200-mg Group P (Slope ¼ 1)
AUC0–t 1.2790 (1.1700–1.3880) o0.0001
AUC0–1 1.3064 (1.1969–1.4158) o0.0001
Cmax 1.0520 (0.9615–1.1426) 0.3402
*The power model, ln(parameter) ¼ a þ b * ln(dose) þ error, was used to estimate the slope, corresponding 90% CI, and
the P value testing dose proportionality (b ¼ 1).
R. Hoover et al.treatment-emergent AE. One participant treated with
delaﬂoxacin discontinued participation in the study
because of an AE of nausea and vomiting considered0.0001
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Figure 2. Mean (SD) plasma concentration-time
curves of delafloxacin after a single IV
1-hour infusion (300-mg) and single
oral (450-mg) administration to heal-
thy volunteers. Top, linear plot; bot-
tom, semilog plot.
January 2016moderate in severity. In the bioavailability study, a
total of 11 participants (19.6%) had an AE. The most
frequently reported AEs were headache (5.4%) and
diarrhea (3.6%). Most AEs were mild and resolved by
the end of the study.DISCUSSION
The increase in hospitalization due to ABSSSIs
reinforces the need for new treatment options.12,13
Limited intravenous and oral treatment options for
ABSSSIs that provide broad-spectrum coverage are
limited because of the increasing prevalence of
resistant pathogens, including MRSA and toxic
effects associated with the current available treat-
ments.14,15 Delaﬂoxacin is an investigational anionic
ﬂuoroquinolone antibiotic that has efﬁcacy for the
treatment of ABSSSI. Both IV (300 mg) and oral
(450 mg) formulations of delaﬂoxacin are currently
in Phase III development for the treatment of
ABSSSIs.
The present study reports on the safety proﬁle,
tolerability, and pharmacokinetic parameters of IV
delaﬂoxacin from 3 studies in healthy volunteers.
Delaﬂoxacin has a good tolerability proﬁle when
administered by intravenous infusion. In the single-
ascending-dose study, the most common AE was
gastrointestinal, which appeared to be dose related.
Most of the AEs were mild in severity. There were no
clinically signiﬁcant ﬁndings from clinical laboratory
data, vital signs, or physical examinations. These
results are consistent with the safety ﬁndings from 2
Phase II studies of ABSSSIs in which IV doses of 300-
mg delaﬂoxacin were found to be well tolerated, with
gastrointestinal AEs the most common AE.6,7 There
were no clinical signiﬁcant ECG results, including no59
Table IV. Mean (SD) pharmacokinetic parameters of delafloxacin after a single IV 1-hour infusion or a single
oral dose to healthy volunteers.
Pharmacokinetic
Parameter Delafloxacin 450-mg Tablet (n ¼ 55) Delafloxacin 300-mg IV Infusion (n ¼ 55)
Tmax, h
* 0.817 (0.50–4.00) 1.00 (0.75–1.13)
Cmax, mg/mL 6.12 (1.96) 10.7 (2.29)
AUC0–t, mg  h/mL 23.3 (7.00) 26.9 (5.78)
AUC0–1, mg  h/mL† 24.2 (6.45) 26.7 (6.03)
F‡ 58.8 (10.5)§
*Median (range).
†n ¼ 42 for the oral tablet and n ¼ 49 for the IV infusion.
‡F was calculated for each participants as (AUC0–1 after oral)(IV dose)/(AUC0–1 after IV)(oral dose).
§n ¼ 37.
Clinical Therapeuticseffect on prolongation of the QT interval in these
Phase I studies, which is consistent with a thorough
QTc study that found no risk for prolongation of the
QTc interval with a delaﬂoxacin supratherapeutic
dose.9
Delaﬂoxacin concentrations decreased in plasma
in a biexponential manner with a terminal half-life of
approximately 12 hours at most dose levels. How-
ever, examination of the plasma proﬁles suggests
the terminal phase would contribute little to the
accumulation of the drug with BID dosing. As
expected, after twice-daily dosing there was minimal
accumulation of delaﬂoxacin at steady state (meanTable V. Statistical analysis of IV infusion (300 mg)
parameters.
Pharmacokinetic Parameter N
Geometric L
Mean
AUC0–1, mg  h/mL
Oral 42 22.97 (21
IV 49 26.20 (24
AUC0–t, mg  h/mL
Oral 55 22.24 (20
IV 55 26.34 (24
Cmax, mg/mL
Oral 55 5.80 (5.
IV 55 10.51 (9.
60Rac ¼ 1.09). Delaﬂoxacin was well distributed with a
Vd at steady state of approximately 35 L, which is
similar to that of total body water. Delaﬂoxacin peak
exposure (Cmax) increased in a dose-proportional
manner in the 300- to 1200-mg dose range evaluated,
whereas total exposure (AUC) increased more than
proportionally with dose (increasing 6.4-fold over
the 4-fold dose range studied). The reasons for the
lack of proportionality were not investigated but
could be caused by saturation of an elimination
pathway. After intravenous administration, most
radioactivity was excreted in urine (65%), with
28% excreted in feces.10 The radioactivity in fecesand oral (450 mg) delafloxacin pharmacokinetic
east Squares
(90% CI)
Ratio Geometric Least Squares
Mean (Oral/IV), % (90% CI)
.61–24.41) 87.68 (83.56–92.00)
.71–27.78)
.99–23.57) 84.45 (80.90–88.15)
.85–27.91)
44–6.17) 55.16 (51.50–59.08)
87–11.19)
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Table VI. Summary of treatment-emergent adverse events regardless of causality.
System Organ Class
No. (%) of Participants by Treatment Group
Single Ascending IV Dose Study (Delafloxacin Dose)
Multiple IV
Dose Study
(Delafloxacin Dose)
Bioavailability IV
vs Oral Study
(Delafloxacin
Dose)
Placebo
300 mg
(n ¼ 12)
450 mg
(n ¼ 8)
600 mg
(n ¼ 8)
750 mg
(n ¼ 8)
900 mg
(n ¼ 8)
1200 mg
(n ¼ 8)
Placebo
(n ¼ 4)
300 mg
(n ¼ 8)
300 mg
IV
(n ¼ 55)
450 mg
Oral
(n ¼ 55)
Gastrointestinal
disorders
1 (10.0) 1 (8.3) 0 0 2 (25.0) 3 (37.5) 7 (87.5) 3 (75.0) 5 (62.5) 2 (3.6) 2 (3.6)
Nausea 1 (10.0) 0 0 0 2 (25.0) 3 (37.5) 4 (50.0) 1 (25.0) 3 (37.5) 1 (1.8) 0
Vomiting 0 0 0 0 0 0 6 (75.0) 0 0 1 (1.8)
Diarrhea 0 0 0 0 1 (12.5) 1 (12.5) 2 (25.0) 0 0 0 2 (3.6)
Abdominal pain 0 0 0 0 1 (12.5) 0 0 2 (50.0) 4 (50.0) 0 0
Retching 0 0 0 0 0 0 1 (12.5) 0 0 0 0
Abdominal
distension
0 1 (8.3) 0 0 0 0 0 0 0 0 0
Abdominal
discomfort
0 0 0 0 0 0 0 0 0 0 1 (1.8)
Infrequent bowel
movements
0 0 0 0 0 0 0 0 0 1 (1.8) 0
Nervous system
disorders
1 (10.0) 1 (8.3) 0 0 1 (12.5) 2 (25.0) 1 (12.5) 3 (75.0) 4 (50.0) 3 (5.5) 1 (1.8)
Headache 1 (10.0) 0 0 0 0 2 (25.0) 0 1 (25.0) 2 (25.0) 2 (3.6) 1 (1.8)
Dizziness 0 1 (8.3) 0 0 0 1 (12.5) 1 (12.5) 2 (50.0) 3 (37.5) 1 (1.8) 0
Presyncope 0 0 0 0 1 (12.5) 0 0 0 0 0 0
Somnolence 1 (10.0) 0 0 0 0 0 0 0 0 0 0
Sinus headache 0 0 0 0 0 0 0 1 (12.5) 0 1 (1.8) 0
Paraesthesia 0 0 0 0 0 0 0 0 1 (12.5) 0 0
Dysgeusia 0 0 0 0 0 0 0 0 0 1 (1.8) 0
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Table VI. (continued).
System Organ Class
No. (%) of Participants by Treatment Group
Single Ascending IV Dose Study (Delafloxacin Dose)
Multiple IV
Dose Study
(Delafloxacin Dose)
Bioavailability IV
vs Oral Study
(Delafloxacin
Dose)
Placebo
300 mg
(n ¼ 12)
450 mg
(n ¼ 8)
600 mg
(n ¼ 8)
750 mg
(n ¼ 8)
900 mg
(n ¼ 8)
1200 mg
(n ¼ 8)
Placebo
(n ¼ 4)
300 mg
(n ¼ 8)
300 mg
IV
(n ¼ 55)
450 mg
Oral
(n ¼ 55)
General disorders and
administration site
conditions
1 (10.0) 0 0 0 0 1 (12.5) 1 (12.5) 3 (75.0) 3 (37.5) 1 (1.8)
Feeling hot 0 0 0 0 0 1 (12.5) 1 (12.5) 0 1 (12.5) 0 0
Asthenia 0 0 0 0 0 1 (12.5) 0 1 (12.5) 0 0 0
Thirst 0 0 0 0 0 1 (12.5) 0 0 0 0 0
Vessel puncture site
swelling
1 (10.0) 0 0 0 0 0 0 0 1 (12.5) 0 0
Injection site pain 0 0 0 0 0 0 0 1 (25.0) 3 (37.5) 0 0
Feeling cold 0 0 0 0 0 0 0 0 1 (12.5) 0 0
Injection site
inﬂammation
0 0 0 0 0 0 0 0 1 (12.5) 0 0
Injection site
reaction
0 0 0 0 0 0 0 1 (12.5) 0 0 0
Edema peripheral 0 0 0 0 0 0 0 1 (12.5) 0 0 0
Energy decreased 0 0 0 0 0 0 0 0 0 0 1 (1.8)
Respiratory, thoracic
and mediastinal
disorders
0 1 (8.3) 0 0 0 1 (12.5) 1 (12.5) 0 0 0 0
Nasal congestion 0 1 (8.3) 0 0 0 1 (12.5) 0 0 0 0 0
Rhinorrhea 0 0 0 0 0 0 1 (12.5) 0 0 0 0
Skin and
subcutaneous tissue
disorders
0 0 0 0 0 1 (12.5) 1 (12.5) 1 (25.0) 3 (37.5) 1 (1.8) 0
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Table VI. (continued).
System Organ Class
No. (%) of Participants by Treatment Group
Single Ascending IV Dose Study (Delafloxacin Dose)
Multiple IV
Dose Study
(Delafloxacin Dose)
Bioavailability IV
vs Oral Study
(Delafloxacin
Dose)
Placebo
300 mg
(n ¼ 12)
450 mg
(n ¼ 8)
600 mg
(n ¼ 8)
750 mg
(n ¼ 8)
900 mg
(n ¼ 8)
1200 mg
(n ¼ 8)
Placebo
(n ¼ 4)
300 mg
(n ¼ 8)
300 mg
IV
(n ¼ 55)
450 mg
Oral
(n ¼ 55)
Hyperhidrosis 0 0 0 0 0 1 (12.5) 0 1 (25.0) 0 0 0
Pruritus 0 0 0 0 0 0 1 (12.5) 0 1 (12.5) 1 (1.8) 0
Dermatitis contact 0 0 0 0 0 0 0 0 2 (25.0) 0 0
Cold sweat 0 0 0 0 0 0 0 1 (12.5) 0 0 0
Dermatitis 0 0 0 0 0 0 0 0 1 (12.5) 0 0
Infections and
infestations
0 1 (8.3) 0 0 0 0 0 0 0 1 (1.8) 0
Vulvovaginal
candidiasis
0 1 (8.3) 0 0 0 0 0 0 0 1 (1.8) 0
Folliculitis 0 0 0 0 0 0 0 0 1 (12.5) 0 0
Eye disorders 0 0 0 0 0 0 0 1 (25.0) 0 0 0
Eye irritation 0 0 0 0 0 0 0 1 (25.0) 0 0 0
Reproductive system
and breast disorders
0 0 0 0 0 0 0 0 1 (12.5) 0 0
Uterine hemorrhage 0 0 0 0 0 0 0 0 1 (12.5) 0 0
Vulvovaginal
discomfort
0 0 0 0 0 0 0 0 1 (12.5) 0 0
Musculoskeletal and
connective tissue
disorders
0 0 0 0 0 0 0 0 0 1 (1.8) 0
Myalgia 0 0 0 0 0 0 0 0 0 1 (1.8) 0
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Clinical Therapeuticswas unchanged delaﬂoxacin, whereas the radio-
activity in urine was either unchanged delaﬂoxacin
(34%–47% of the dose) or delaﬂoxacin glucuronide
(15%–22% of the dose). The metabolism of
delaﬂoxacin to glucuronides is primarily mediated
by UGT1A1 and UGT1A3 (data on ﬁle at Melinta
Therapeutics). In vitro, delaﬂoxacin is not a substrate
of transporters OAT1, OAT3, OCT1, OCT2,
OATP1B1, or OATP1B3, but it is a probable subs-
trate of breast cancer resistance protein and possibly
a substrate of P-glycoprotein (data on ﬁle at Melinta
Therapeutics).
The present results indicate that CLr represents
approximately 35% to 40% of the total delaﬂoxacin
clearance. These results are consistent with a radio-
labeled mass-balance study of intravenous [14C]dela-
ﬂoxacin, which found that most of the radioactivity
excreted in urine was unchanged delaﬂoxacin.10
Delaﬂoxacin clearance is reduced in patients with
renal impairment and in patients with end-stage renal
disease undergoing dialysis.16
Delaﬂoxacin was well absorbed after administra-
tion of the 450-mg tablet, with a mean absolute
bioavailability of 58.8%. The 450-mg oral dose was
developed to match the exposure of the 300-mg IV
dosage. The total exposure (AUC0–t or AUC0–1) to
delaﬂoxacin was equivalent after IV (300 mg) and
oral (450 mg) administration. The peak exposure was
not equivalent for the 2 formulations, with the Cmax
being lower for the tablet formulation. Lack of
equivalence for peak exposure is not considered
clinically important because the efﬁcacy of delaﬂox-
acin is best correlated with the AUC/MIC ratio,
similarly to other ﬂuoroquinolones.17 A lower Cmax
with the oral formulation may be an advantage
because higher doses exposures have been associated
with more gastrointestinal AEs.18 Equivalence of
delaﬂoxacin total exposure will allow for maintain-
ing efﬁcacious exposures with the switch between the
intravenous and oral formulations. The ability to
change from intravenous to oral may reduce the dura-
tion of hospitalization and the need for indwelling
catheters, thus reducing the cost of treatment for some
patients.CONCLUSIONS
In summary, the pharmacokinetic parameters of dela-
ﬂoxacin after IV (300 mg) and oral (450 mg)64administration are comparable, supporting that a
switch between the 2 formulations would be accept-
able. The results reveal suitable pharmacokinetic
parameters and good tolerability for delaﬂoxacin
when given twice daily as 300-mg intravenous
1-hour infusions. The pharmacokinetic parameters of
IV delaﬂoxacin suggest steady state should be
achieved within 2 to 3 days, and, as expected, minimal
accumulation was observed after twice-daily dosing in
a 14-day study. Renal elimination of unchanged
delaﬂoxacin accounts for approximately 30% to
40% of the total clearance after intravenous admin-
istration. Intravenous delaﬂoxacin was well tolerated
in healthy volunteers after single- and multiple-dose
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